Obermatt
See Similar Stocks →

Avadel Pharmaceuticals

NMQ:AVDL · IE00BDGMC594
PharmaceuticalsSmall

360

70
Medium confidence — indicative
EV / EBIT10
Price / Owner Earnings27
Owner Earnings Yield63
Dividend Yield1
Price/Sales28
EV / Gross Profit32
Price/Book5
Return on Capital53
Cash Return on Capital100
Return on Equity100
EBIT Margin19
Gross Profitability100
Cash Conversion66
Accruals90
Owner Earnings Margin88
Sales growth92
Profit Growth38
Owner Earnings Growth100
Reinvestment13
Price momentum99
Debt load53
Refinancing48
Debt Payback100
Liquidity30
Analyst ratings5
Expectations trend50
Market mood81
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Avadel Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryIreland
IndustryPharmaceuticals
SizeSmall
TypePrivate Company
ExchangeNASDAQGM
Founded2015
Employees162
Websiteavadel.com
ISINIE00BDGMC594
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Sleep TechnologyNeurologyCentral Nervous SystemBiotechnologyInformation TechnologyPharmaceutical

Description

Avadel Pharmaceuticals plc (Avadel) operates as a biopharmaceutical company. LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in patients seven years of age and o…

Analysis

Quality compounder

Avadel Pharmaceuticals plc earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 29.0×; owner earnings: the cash an owner could take out each year.

Growth is mixed; the safety picture is adequate. The company scores 18/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
8
2026

All-time high

12

Mar 2026

All-time low

8

Jun 2026

Average rank

10

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
28
—
—
—
Price/Earnings
20
—
—
—
Price/Book
5
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
11
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Avadel Pharmaceuticals with its peers
Jazz Pharmaceuticals
NSQ:JAZZ
91
CountryIreland
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sanofi India
NSI:SANOFI
56
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cosmo Pharmaceuticals
SWX:COPN
47
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
GH Research
NMQ:GHRS
57
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Virbac
PAR:VIRP
58
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sandoz
SWX:SDZ
18
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →